PharmaTelevision - Damian Maron, CEO of Trophos talks about the consortiums they are heading and explains their focus on orphan drugs.

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Damian Maron, CEO of Trophos talks about the consortiums they are heading and explains their focus on orphan drugs.

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Damian Marron, CEO of Trophos

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Trophos: Focus on Orphan drug and funding

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here at BIO-Europe in Milan, in spring 2011. On this show I have Damian Marron, who is CEO of a company called Trophos which is based in Marseille in France, welcome to the show.

Damian Marron:

Thank you Fintan.

Fintan Walton:

Damian, could you tell us the history of Trophos?

Damian Marron:

Yes, Trophos is a spin out from the University of Marseille in late '99, 2000 set by founding scientist and a couple of local entrepreneurs and then taken on by VC's afterwards.

Fintan Walton:

Okay, now today the company is recognized as a specialty orphan focused company, orphan drug focus company it's a private company so tell us how the company is actually funded?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Damian Marron

CEO

Damian Marron Ph.D serves as Chief Executive Officer of Trophos SA. Mr. Marron has over 20 years biotechnology and pharmaceutical industry experience. He served as Vice President of Corporate Development of Nicox SA from 2002 to May 30, 2008. He has great experience of pharmaceutical industry at the international level, in particular in the fields of the licenses, research and development and, of the sale/sellings and marketing. He served as Head of the European division of Development Business at 3M Pharmaceuticals since 1997, where he responsible for several Distribution and licensing agreements. From 1995 to 1997, Mr. Marron occupied the position of Person in charge for the Office of the United Kingdom within Orphan Europe, it specialized in the orphan drugs. From 1992 to 1995, he served with Rhone-Poulenc Rorer, initially like Coordinator of Research Clinical Senior in oncology then like Responsible for the Clinical Operations within joint venture the ChugaiRhone-Poulenc Rorer. From 1987 to 1992, he occupied the functions of attache of Research Clinical in the field of the central nervous system and of researcher in cellular biology at Glaxo. Mr. Marron obtained his diploma in pharmacology with mention of the University of Liverpool in 1985 and supplemented by research tasks in the field of the monoclonal antibodies within the service of cancerous radiotherapy of the University.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

Trophos

Trophos is a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology . Trophos is a late stage clinical stage company with a pipeline of original molecules in development for the motoneuron diseases , amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) and spinal muscular atrophy (SMA) and for cardiac ischemia-reperfusion injury and research projects in other neurological conditions. Trophos discovery strategy involves screening chemical collections of small molecules on models of sick neurons, using the class of neurons affected in each type of disease, and is based on our unique expertise in cell-based models and imaging instrumentation. Employing this approach, the Company has identified a novel and proprietary cholesterol-oxime chemistry generating a pipeline of drug candidates that enhance the function and survival of stressed cells via modulation of dysfunctional mitochondria through interactions at the permeability transition pore (mPTP). The Trophos management team brings together decades of experience in drug discovery and development from biotech and major pharmaceutical companies ensuring that drug candidates are developed using rigorous lead optimization, preclinical evaluation and clinical testing procedures. Trophos was founded in 1999, is based in Marseille, France and currently has 32 employees.